Philly Risperdal Trial Settles On Day Of Opening Arguments

Law360, Philadelphia (May 27, 2015, 1:41 PM EDT) -- Johnson & Johnson reached a settlement with a California boy on Wednesday just hours before attorneys were set to begin opening arguments in what would have been the third opportunity for a Philadelphia jury to weigh the connection between antipsychotic drug Risperdal and abnormal breast growth in youth.

A spokeswoman for Johnson & Johnson unit Janssen Pharmaceuticals Inc. confirmed the settlement to plaintiff Christopher Walker's case — part of Philadelphia's mass tort program over the drug — but said the terms were confidential.

Stephen Sheller of Sheller PC, representing Walker, said Tuesday that he anticipated spending Wednesday morning arguing final motions...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!